Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Vitamins
More

Other
Feedback
Home
Top
Results
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 28% Improvement Relative Risk Improvement 26% HCQ for COVID-19  Nachega et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 766 patients in DR Congo Lower mortality (p=0.17) and greater improvement (p=0.13), not sig. c19hcq.org Nachega et al., The American J. Tropi.., Oct 2020 Favors HCQ Favors control

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

Nachega et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240
Oct 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 766 hospitalized patients in DRC showing mortality reduced from 29% to 11%, and improvement at 30 days increased from 65% to 84%.
Mortality cox regression adjusted hazard ratio aHR 0.26, p < 0.001
Risk of no improvement adjusted odds ratio aOR 0.28, p < 0.001
Using marginal structural model analysis these risks became:
Mortality MSM adjusted odds ratio aOR 0.65, p = 0.166
Risk of no improvement MSM adjusted odds ratio aOR = 0.65, p = 0.132
Median age 46, 630 treated with CQ+AZ.
Although the 28% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 247 mortality results to date.
risk of death, 27.6% lower, RR 0.72, p = 0.17, treatment 69 of 630 (11.0%), control 28 of 96 (29.2%), NNT 5.5, adjusted per study, odds ratio converted to relative risk.
risk of no improvement, 25.8% better, RR 0.74, p = 0.13, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nachega et al., 2 Oct 2020, retrospective, database analysis, DR Congo, peer-reviewed, median age 46.0, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit